Technology platforms and capabilities
Our pursuit of excellence is underpinned by world-leading capabilities and expertise through our integrated network of Technology Platforms.
RNAte Technology Platform
The RNAte platform is designed to address the need for testing the immunoreactivity of RNA-based products, especially in established human cell models. The platform places a high priority on human induced pluripotent stem cell (iPSC) models for sensitive and accurate detection of immune responses.
Leveraging robotic automation in testing services enables high throughput applications for library screening or testing of different conditions, thereby aiding the optimisation of new product development. Using iPSC models can reduce the risk of clinical trials failure and has the potential to accelerate the development of new RNA and mRNA products in the manufacturing pipeline.
General enquiries | enquiry@rnate.com.au
Hudson Cell Therapies
Hudson Cell Therapies provides a facility for the safe, efficient and rapid manufacturing of human blood and tissue products. Hudson Cell Therapies allows clinicians based in the Monash Medical Precinct and elsewhere to have blood products processed outside the Melbourne CBD for the first time, improving accessibility for clinical trials.
Operating within a PC2 & ISO 8 certified clean room facility and housing a cryopreservation suite operated to ISO 15189 standards, Hudson Cell Therapies is qualified to receive, store and distribute human cellular therapy products in support of multi-site clinical cell therapy trials.
General enquiries | hudson-ct@hudson.org.au
Flow cytometry
Histology
Genomics
Micro imaging
Proteomics
